32 Irinotecan specifically targets topoisomerase I (topoI), and is used to treat various solid 33 tumors, but only 13-32% of patients respond to the therapy. Now, it is understood that the 34 rapid rate of topoI degradation in response to irinotecan causes irinotecan resistance. We 35 have published that the deregulated DNA-PKcs kinase cascade ensures rapid degradation 36 of topoI and is at the core of the drug resistance mechanism of topoI inhibitors, including 37 irinotecan. We also identified CTD small phosphatase 1 (CTDSP1) (a nuclear 38 phosphatase) as a primary upstream regulator of DNA-PKcs in response to topoI 39 inhibitors. Previous reports showed that rabeprazole, a proton pump inhibitor (PPI) 40 inhibits CTDSP1 activity. The purpose of this study was to confirm the effects of 41 rabeprazole on CTDSP1 activity and its impact on colon cancer. Using HCT116 and 42 HT29, with high and low CTDSP1 expression respectively and a retrospective analysis 43 of patients receiving irinotecan with or without rabeprazole have indicated the effect of 44 CTDSP1 in irinotecan response. These results indicate that CTDSP1 promotes 45 sensitivity to irinotecan and rabeprazole prevents this effect, resulting in drug resistance.
272 higher level was observed in overexpressing cells ( Fig 3A) . The Vector control and 273 CTDSP1-expressing HT29 cells were then treated with SN38, and topoI protein level was 274 analyzed after 90 and 180 min. The data clearly demonstrates that in cells with higher 275 CTDSP1, the topoI degradation was minimal. In contrast, a significantly lower level of
topoI was observed in HT29-vector cells. This indicates that overexpression of CTDSP1
277 in HT29 regulates SN-38-induced proteasomal degradation of topoI ( Fig 3B) . The cell 278 viability assay indicated that topoI stabilization by CTDSP1 overexpression restores SN-279 38 drug sensitivity ( Fig 3C) . 289 290 CTDSP1 activates DNA-PKcs and enhances topo I degradation 291 Once we determined that HCT116 and HT29 have differential expression of CTDSP1, 292 we asked if DNA-PKcs activation status is different in these two-cell lines. Cell lysates 293 from these cells were subjected to immunoblot analysis with anti-DNA-PKcs-pS2056.
294 The results indicated a higher level of phosphorylated DNA-PKcs in HT29 cells ( Fig 4A) . 298 and the data clearly demonstrated that silencing of CTDSP1 significantly enhanced 299 phosphorylated DNA-PKcs in HCT116 cells ( Fig 4B) . This was observed by GFP 300 florescence level by confocal microscopy (Fig 4C) . 319 demonstrated that topoI was degraded at 270 min ( Fig 5A) . To visualize the rate of topoI 320 degradation, HCT116-topoI-GFP cells were treated first with rabeprazole, and then 321 treated with 5 and 10 μM SN-38 for 60 min (Fig 5B) . A significant reduction of topoI-322 GFP florescence at 10 μM rabeprazole at 60 min clearly indicated a rapid rate of topoI 323 degradation in cells that were treated with rabeprazole. 
